Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | FAP | Q12884 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716265 | 1.00 | HDAC1 (0.44) | HDAC1HDAC6SMYD3DPP4FAP | |
| SCHEMBL14590636 | 0.77 | NOTUM (0.53) | HDAC6HDAC8PDK1PDK2PDK3 | |
| SCHEMBL16324997 | 0.75 | AKR1C3 (0.41) | HDAC6HDAC8KDM2BPDK1PDK2 | |
| SCHEMBL4716258 | 0.75 | KDM2B (0.44) | SMYD3KDM2B | |
| SCHEMBL3287771 | 0.75 | HDAC6 (0.54) | HDAC6SMYD3 | |
| Iodide SCHEMBL4716431 | 0.73 | USP30 (0.47) | HDAC1 | |
| Iodide SCHEMBL4716430 | 0.73 | USP30 (0.47) | HDAC1 | |
| SCHEMBL4711157 | 0.71 | ERCC1 (0.45) | HDAC1HDAC6 | |
| SCHEMBL4711151 | 0.71 | ERCC1 (0.45) | HDAC1HDAC6 | |
| SCHEMBL14626051 | 0.70 | AKR1C3 (0.42) | HDAC6HDAC8PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1325910-B1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
| US-6849622-B2 | Aliphatic nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| US-20040229926-A1 | Aliphatic nitrogen - containing 5 - membered ring compound | TANABE SEIYAKU CO., LTD. | 2004-11-18 | — | — | US | disclosed |
| US-20040063935-A1 | Aliphatic nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| CN-1468217-A | Aliphatic nitrogenous five-membered ring compounds | ������ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| EP-1325910-A1 | ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063935-A1 | Aliphatic nitrogenous five-membered ring compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SCN5A, CYP11B1 | HDAC1 267/4885HDAC6 295/4885SMYD3 1076/4885 |
| US-20040229926-A1 | Aliphatic nitrogen - containing 5 - membered ring compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B1, CYP11B2 | HDAC1 184/4885HDAC6 314/4885SMYD3 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.